Nabriva Therapeutics plc [NASDAQ: NBRV] price plunged by -7.05 percent to reach at -$0.11. The company report on April 3, 2021 that Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 106,000 ordinary shares of Nabriva Therapeutics as an inducement to two newly-hired employees. These grants included a non-statutory option to purchase 100,000 ordinary shares of Nabriva Therapeutics awarded to Daniel Dolan, Nabriva’s newly appointed Chief Financial Officer. Both awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires’ employment compensation.
The stock options were granted effective March 31, 2021 with an exercise price of $1.66 per share, which is equal to the closing price of Nabriva Therapeutics’s ordinary shares on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 25% of the original number of shares vesting on the annual anniversary of the grant date until fully vested, subject to the employee’s continued service with the Company through the applicable vesting dates. The stock option awards were approved by Nabriva Therapeutics’ Compensation Committee and were granted as an inducement material to each employee’s acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options is subject to the terms and conditions of a stock option agreement covering the grant and Nabriva Therapeutics’ 2021 Inducement Share Incentive Plan.
A sum of 1512636 shares traded at recent session while its average daily volume was at 2.23M shares. Nabriva Therapeutics plc shares reached a high of $1.58 and dropped to a low of $1.42 until finishing in the latest session at $1.45.
Guru’s Opinion on Nabriva Therapeutics plc [NBRV]:
Wedbush have made an estimate for Nabriva Therapeutics plc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 19, 2020. The new note on the price target was released on May 02, 2019, representing the official price target for Nabriva Therapeutics plc stock. Previously, the target price had yet another drop from $9 to $7, while H.C. Wainwright kept a Buy rating on NBRV stock.
The Average True Range (ATR) for Nabriva Therapeutics plc is set at 0.16, with the Price to Sales ratio for NBRV stock in the period of the last 12 months amounting to 10.20. The Price to Book ratio for the last quarter was 0.71, with the Price to Cash per share for the same quarter was set at 1.18.
NBRV Stock Performance Analysis:
Nabriva Therapeutics plc [NBRV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.18. With this latest performance, NBRV shares dropped by -17.61% in over the last four-week period, additionally sinking by -75.83% over the last 6 months – not to mention a drop of -72.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBRV stock in for the last two-week period is set at 31.95, with the RSI for the last a single of trading hit 27.35, and the three-weeks RSI is set at 34.20 for Nabriva Therapeutics plc [NBRV]. The present Moving Average for the last 50 days of trading for this stock 2.2132, while it was recorded at 1.6000 for the last single week of trading, and 4.4535 for the last 200 days.
Insight into Nabriva Therapeutics plc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Nabriva Therapeutics plc [NBRV] shares currently have an operating margin of -1315.42 and a Gross Margin at +68.45. Nabriva Therapeutics plc’s Net Margin is presently recorded at -1382.22.
Return on Total Capital for NBRV is now -113.39, given the latest momentum, and Return on Invested Capital for the company is -121.27. Return on Equity for this stock declined to -186.76, with Return on Assets sitting at -91.10. When it comes to the capital structure of this company, Nabriva Therapeutics plc [NBRV] has a Total Debt to Total Equity ratio set at 23.32. Additionally, NBRV Total Debt to Total Capital is recorded at 18.91, with Total Debt to Total Assets ending up at 13.22. Long-Term Debt to Equity for the company is recorded at 17.16, with the Long-Term Debt to Total Capital now at 13.92.
Reflecting on the efficiency of the workforce at the company, Nabriva Therapeutics plc [NBRV] managed to generate an average of -$965,056 per employee. Receivables Turnover for the company is 1.51 with a Total Asset Turnover recorded at a value of 0.07.Nabriva Therapeutics plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.80 and a Current Ratio set at 3.10.
NBRV Stock EPS
With the latest financial reports released by the company, Nabriva Therapeutics plc posted -2.5/share EPS, while the average EPS was predicted by analysts to be reported at -2.64/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 5.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBRV.
Nabriva Therapeutics plc [NBRV] Insider Position Details
There are presently around $5 million, or 13.50% of NBRV stock, in the hands of institutional investors. The top three institutional holders of NBRV stocks are: FMR LLC with ownership of 1,429,259, which is approximately New of the company’s market cap and around 1.00% of the total institutional ownership; FRAZIER MANAGEMENT LLC, holding 425,650 shares of the stock with an approximate value of $0.62 million in NBRV stocks shares; and MORGAN STANLEY, currently with $0.57 million in NBRV stock with ownership of nearly New of the company’s market capitalization.
Positions in Nabriva Therapeutics plc stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 30 institutional holders increased their position in Nabriva Therapeutics plc [NASDAQ:NBRV] by around 3,370,711 shares. Additionally, 0 investors decreased positions by around 0 shares, while 0 investors held positions by with 0 shares. The mentioned changes placed institutional holdings at 3,370,711 shares, according to the latest SEC report filing. NBRV stock had 30 new institutional investments in for a total of 3,370,711 shares, while 0 institutional investors sold positions of 0 shares during the same period.